View our Special Meeting Proxy Statement.
View our Special Meeting Reminder Letter.
Your vote is IMPORTANT!
Please vote your proxy online now or by phone by dialing 866-243-5513.
October 10, 2025
9:00 AM PT
You must register in order to attend the meeting.
Our report on activities & financial performance
throughout the year.
View an enhanced version of information about our annual meeting & matters to be voted upon.
Request paper copies of the above proxy materials online now, by email or by phone by dialing 866-648-8133.
Your vote is IMPORTANT!
Please vote your proxy online now or by phone by dialing 866-243-5513.
October 17, 2025
10:00 AM PT
You must register in order to attend the meeting.
Palisade Bio is a biopharmaceutical company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. The Company believes that addressing the disruption of the intestinal barrier can fundamentally change the way diseases are treated and establish new standards of patient care.
Palisade Bio’s lead program, PALI-2108 is a microbiota-activated PDE4 inhibitor prodrug being developed for the treatment of moderate-to-severe ulcerative colitis and is advancing toward the completion of IND-enabling studies and an IND filing. The Company’s second lead program, PALI-1908, is being evaluated in preclinical development for the treatment of fibro stenotic Crohn’s Disease.